PubMed

Robust control for convection suppression in a fluid layer: The effects of boundary properties, actuator lag, and major parameter uncertainties.

Or AC, Speyer JL.

Phys Rev E Stat Nonlin Soft Matter Phys. 2006 Apr;73(4 Pt 2):046307. Epub 2006 Apr 19.PMID: 16711929 [PubMed]Related articles

Conductivity and gating of silicon ringchains.

Speyer JL, Ovchinnikov IV, Neuhauser D, Baugh D.

J Chem Phys. 2005 Sep 22;123(12):124704.PMID: 16392508 [PubMed]Related articles

Gain-scheduled controller for the suppression of convection at high Rayleigh number.

Or AC, Speyer JL.

Phys Rev E Stat Nonlin Soft Matter Phys. 2005 Apr;71(4 Pt 2):046302. Epub 2005 Apr 4.PMID: 15903781 [PubMed]Related articles

Control of satellite clusters in elliptic orbit with limited communication.

Chichka DF, Belanger G, Speyer JL.

Ann N Y Acad Sci. 2004 May;1017:177-89.PMID: 15220147 [PubMed]Related articles

Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival.

Rosenberg E, Demopoulos RI, Zeleniuch-Jacquotte A, Yee H, Sorich J, Speyer JL, Newcomb EW.

Hum Pathol. 2001 Aug;32(8):808-13.PMID: 11521224 [PubMed - indexed for MEDLINE]Related articles

A phase II double-blind randomized study of the simultaneous administration of recombinant human interleukin-6 and recombinant human granulocyte colony-stimulating factor following paclitaxel and carboplatin chemotherapy in patients with advanced epithelial ovarian cancer.

Hochster H, Speyer JL, Mandeli JP, Runowicz C, Wadler S, Berk G, Wallach R, Holland JF.

Gynecol Oncol. 1999 Mar;72(3):292-7.PMID: 10053098 [PubMed - indexed for MEDLINE]Related articles

Doxorubicin-induced cardiomyopathy.

Muggia FM, Speyer JL.

N Engl J Med. 1999 Feb 25;340(8):654-5. No abstract available. PMID: 10049088 [PubMed - indexed for MEDLINE]Related articles

Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors.

Newcomb EW, Sosnow M, Demopoulos RI, Zeleniuch-Jacquotte A, Sorich J, Speyer JL.

Am J Pathol. 1999 Jan;154(1):119-25.PMID: 9916926 [PubMed - indexed for MEDLINE]Related articlesFree article

Phase I/II study of PIXY321 in combination with cyclophosphamide and carboplatin in the treatment of ovarian cancer.

Runowicz CD, Mandeli J, Speyer JL, Wadler S, Hochster H, Garrison L, Holland JF.

Am J Obstet Gynecol. 1996 Apr;174(4):1151-9; discussion 1159-60.PMID: 8623842 [PubMed - indexed for MEDLINE]Related articles

A phase I trial of cyclosphosphamide and carboplatinum combined with interleukin-3 in women with advanced-stage ovarian cancer.

Speyer JL, Mandeli J, Hochster H, Runowicz C, Wadler S, Wallach R, Cohen C, Oette D, Sorich J, Demakos E, et al.

Gynecol Oncol. 1995 Mar;56(3):387-94.PMID: 7705673 [PubMed - indexed for MEDLINE]Related articles

Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin.

Hochster H, Liebes L, Wadler S, Oratz R, Wernz JC, Meyers M, Green M, Blum RH, Speyer JL.

J Natl Cancer Inst. 1992 Nov 18;84(22):1725-30.PMID: 1433357 [PubMed - indexed for MEDLINE]Related articles

Intraperitoneal carboplatin: rationale and experience.

Speyer JL, Sorich J.

Semin Oncol. 1992 Feb;19(1 Suppl 2):107-13. Review.PMID: 1411621 [PubMed - indexed for MEDLINE]Related articles

Phase I study of doxorubicin, ICRF-187 and granulocyte/macrophage-colony-stimulating factor.

Walsh C, Blum RH, Oratz R, Goldenberg A, Downey A, Speyer JL.

J Cancer Res Clin Oncol. 1992;118(1):61-6.PMID: 1729261 [PubMed - indexed for MEDLINE]Related articles

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.

Speyer JL, Green MD, Zeleniuch-Jacquotte A, Wernz JC, Rey M, Sanger J, Kramer E, Ferrans V, Hochster H, Meyers M, et al.

J Clin Oncol. 1992 Jan;10(1):117-27. Erratum in: J Clin Oncol 1992 May;10(5):867. PMID: 1727913 [PubMed - indexed for MEDLINE]Related articles

Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine.

Oratz R, Dugan M, Roses DF, Harris MN, Speyer JL, Hochster H, Weissman J, Henn M, Bystryn JC.

Cancer Res. 1991 Jul 15;51(14):3643-7.PMID: 2065322 [PubMed - indexed for MEDLINE]Related articlesFree article

Cardioxane--ICRF-187 towards anticancer drug specificity through selective toxicity reduction.

Koning J, Palmer P, Franks CR, Mulder DE, Speyer JL, Green MD, Hellmann K.

Cancer Treat Rev. 1991 Mar;18(1):1-19. Review. No abstract available. PMID: 1933909 [PubMed - indexed for MEDLINE]Related articles

Phase I and pharmacologic evaluation of intraperitoneal 5-fluoro-2'-deoxyuridine.

Muggia FM, Chan KK, Russell C, Colombo N, Speyer JL, Sehgal K, Jeffers S, Sorich J, Leichman L, Beller U, et al.

Cancer Chemother Pharmacol. 1991;28(4):241-50.PMID: 1831736 [PubMed - indexed for MEDLINE]Related articles

ICRF-187 (ADR-529) cardioprotection against anthracycline-induced cardiotoxicity: clinical and preclinical studies.

Green MD, Alderton P, Sobol MM, Gross J, Muggia FM, Speyer JL.

Cancer Treat Res. 1991;58:101-17. Review. No abstract available. PMID: 1683780 [PubMed - indexed for MEDLINE]Related articles

A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer.

Speyer JL, Green MD, Sanger J, Zeleniuch-Jacquotte A, Kramer E, Rey M, Wernz JC, Blum RH, Hochester H, Meyers M, et al.

Cancer Treat Rev. 1990 Sep;17(2-3):161-3. No abstract available. PMID: 2125531 [PubMed - indexed for MEDLINE]Related articles

Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trial.

Oratz R, Speyer JL, Wernz JC, Hochster H, Meyers M, Mischak R, Spitler LE.

J Biol Response Mod. 1990 Aug;9(4):345-54.PMID: 2395000 [PubMed - indexed for MEDLINE]Related articles

Phase II study of esorubicin (4'deoxydoxorubicin) in anthracycline naive patients with ovarian cancer.

Green MD, Speyer JL, Wernz JC, Colombo N, Beller U, Muggia FM, Beckman EM.

Invest New Drugs. 1990 Aug;8(3):333-6.PMID: 2272774 [PubMed - indexed for MEDLINE]Related articles

Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy.

Speyer JL, Beller U, Colombo N, Sorich J, Wernz JC, Hochster H, Green M, Porges R, Muggia FM, Canetta R, et al.

J Clin Oncol. 1990 Aug;8(8):1335-41.PMID: 2199620 [PubMed - indexed for MEDLINE]Related articles

Good tolerance of weekly oral idarubicin: (4-demethoxydaunorubicin): a phase I study with pharmacology.

Hochster H, Green M, Liebes L, Speyer JL, Wernz J, Blum R, Muggia F.

Cancer Chemother Pharmacol. 1990;26(4):297-300.PMID: 2369795 [PubMed - indexed for MEDLINE]Related articles

Evidence of the selective alteration of anthracycline activity due to modulation by ICRF-187 (ADR-529).

Green MD, Alderton P, Gross J, Muggia FM, Speyer JL.

Pharmacol Ther. 1990;48(1):61-9. Review.PMID: 2125733 [PubMed - indexed for MEDLINE]Related articles

Modulation of the effect of anthracycline efficacy and toxicity by ICRF-187.

Blum RH, Walsh C, Green MD, Speyer JL.

Cancer Invest. 1990;8(2):267-8. No abstract available. PMID: 2119245 [PubMed - indexed for MEDLINE]Related articles

Phase IB study of low-dose intraperitoneal recombinant interleukin-2 in patients with refractory advanced ovarian cancer: rationale and preliminary report.

Beller U, Chachoua A, Speyer JL, Sorich J, Dugan M, Liebes L, Hayes R, Beckman EM.

Gynecol Oncol. 1989 Sep;34(3):407-12.PMID: 2788602 [PubMed - indexed for MEDLINE]Related articles

Induction of tumor-infiltrating lymphocytes in human malignant melanoma metastases by immunization to melanoma antigen vaccine.

Oratz R, Cockerell C, Speyer JL, Harris M, Roses D, Bystryn JC.

J Biol Response Mod. 1989 Aug;8(4):355-8.PMID: 2754436 [PubMed - indexed for MEDLINE]Related articles

Phase I study of the combination of alpha-2 interferon and cisplatinum.

Walsh C, Speyer JL, Wernz J, Hochster H, Grossberg H, Chachoua A, Molinaro P, Meyers M, Blum RH.

J Biol Response Mod. 1989 Feb;8(1):11-5.PMID: 2921608 [PubMed - indexed for MEDLINE]Related articles

Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients.

Colombo N, Speyer JL, Green M, Canetta R, Beller U, Wernz JC, Meyers M, Widman T, Blum RH, Piccart M, et al.

Cancer Chemother Pharmacol. 1989;23(5):323-8.PMID: 2650904 [PubMed - indexed for MEDLINE]Related articles

Intraperitoneal cisplatin with i.v. therapy.

Speyer JL.

Cancer Invest. 1989;7(6):613-4. No abstract available. Erratum in: Cancer Invest 1990;8(3-4):449. PMID: 2630012 [PubMed - indexed for MEDLINE]Related articles

Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer.

Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, Dubin N, Ferrans V, Stecy P, Zeleniuch-Jacquotte A, et al.

N Engl J Med. 1988 Sep 22;319(12):745-52.PMID: 3137469 [PubMed - indexed for MEDLINE]Related articles

Phase I trial of escalating dose doxorubicin administered concurrently with alpha 2-interferon.

Green MD, Speyer JL, Hochster HS, Liebes LF, Dunleavy S, Widman T, Wernz JC, Blum RH, Spiegel RJ, Muggia FM.

Cancer Res. 1988 May 1;48(9):2574-8.PMID: 3356017 [PubMed - indexed for MEDLINE]Related articlesFree article

Immunogenicity of a polyvalent melanoma antigen vaccine in humans.

Bystryn JC, Oratz R, Harris MN, Roses DF, Golomb FM, Speyer JL.

Cancer. 1988 Mar 15;61(6):1065-70.PMID: 3342366 [PubMed - indexed for MEDLINE]Related articles

The disposition of carboplatin in ovarian cancer patients.

Gaver RC, Colombo N, Green MD, George AM, Deeb G, Morris AD, Canetta RM, Speyer JL, Farmen RH, Muggia FM.

Cancer Chemother Pharmacol. 1988;22(3):263-70.PMID: 3044634 [PubMed - indexed for MEDLINE]Related articles

A reassessment of the role of second-look laparotomy in advanced ovarian cancer.

Ho AG, Beller U, Speyer JL, Colombo N, Wernz J, Beckman EM.

J Clin Oncol. 1987 Sep;5(9):1316-21.PMID: 3625253 [PubMed - indexed for MEDLINE]Related articles

Treatment of metastatic malignant melanoma with dacarbazine and cisplatin.

Oratz R, Speyer JL, Green M, Blum R, Wernz JC, Muggia FM.

Cancer Treat Rep. 1987 Sep;71(9):877-8. No abstract available. PMID: 3621224 [PubMed - indexed for MEDLINE]Related articles

Advanced ovarian cancer: three-year results of a 6-8 month, 2-drug cisplatin-containing regimen.

Piccart MJ, Speyer JL, Wernz JC, Noumoff J, Beller U, Beckman M, Dubin N, Demopoulos R, Muggia F.

Eur J Cancer Clin Oncol. 1987 Jun;23(6):631-41.PMID: 3653186 [PubMed - indexed for MEDLINE]Related articles

Can intraperitoneal chemotherapy alter the natural course of ovarian cancer?

Beller U, Beckman EM, Speyer JL.

J Clin Oncol. 1986 Jun;4(6):1015. No abstract available. PMID: 3711955 [PubMed - indexed for MEDLINE]Related articles

Cisplatin and vinblastine chemotherapy for metastatic non-small cell carcinoma followed by irradiation in patients with regional disease.

Blum RH, Cooper J, Schmidt AM, Ashinoff R, Collins A, Wernz JC, Speyer JL, Boyd A, Muggia FM.

Cancer Treat Rep. 1986 Mar;70(3):333-7.PMID: 3955544 [PubMed - indexed for MEDLINE]Related articles

Prolonged treatment schedules with intraperitoneal 5-fluorouracil diminish the local-regional nature of drug distribution.

Sugarbaker PH, Klecker RW, Gianola FJ, Speyer JL.

Am J Clin Oncol. 1986 Feb;9(1):1-7.PMID: 3953487 [PubMed - indexed for MEDLINE]Related articles

Activity of epirubicin in pancreatic carcinoma.

Hochster H, Green MD, Speyer JL, Wernz JC, Blum RH, Muggia FM.

Cancer Treat Rep. 1986 Feb;70(2):299-300. No abstract available. PMID: 3456273 [PubMed - indexed for MEDLINE]Related articles

Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; phase II trial.

Hochster HS, Green MD, Blum RH, Wernz JC, Speyer JL, Muggia FM.

Invest New Drugs. 1986;4(3):275-8.PMID: 3469171 [PubMed - indexed for MEDLINE]Related articles

Ovarian cancer: new therapeutic concepts, renewed optimism.

Muggia FM, Piccart MJ, Speyer JL.

Ann Intern Med. 1985 Nov;103(5):795-7. No abstract available. PMID: 4051356 [PubMed - indexed for MEDLINE]Related articles

Intraperitoneal chemotherapy: technical experience at five institutions.

Piccart MJ, Speyer JL, Markman M, ten Bokkel Huinink WW, Alberts D, Jenkins J, Muggia F.

Semin Oncol. 1985 Sep;12(3 Suppl 4):90-6.PMID: 4048981 [PubMed - indexed for MEDLINE]Related articles

The rationale behind intraperitoneal chemotherapy in gastrointestinal malignancies.

Speyer JL.

Semin Oncol. 1985 Sep;12(3 Suppl 4):23-8.PMID: 4048973 [PubMed - indexed for MEDLINE]Related articles

Prospective randomized trial of intravenous v intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer.

Sugarbaker PH, Gianola FJ, Speyer JL, Wesley R, Barofsky I, Myers CE.

Semin Oncol. 1985 Sep;12(3 Suppl 4):101-11.PMID: 3901269 [PubMed - indexed for MEDLINE]Related articles

Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast.

Speyer JL, Green MD, Dubin N, Blum RH, Wernz JC, Roses D, Sanger J, Muggia FM.

Am J Med. 1985 Apr;78(4):555-63.PMID: 3838618 [PubMed - indexed for MEDLINE]Related articles

Phase II trial of cyclophosphamide and cis-platinum for non-small cell bronchogenic carcinoma.

Schmidt AM, Blum RH, Clayton M, Speyer JL, Bottino J, Muggia FM.

Am J Clin Oncol. 1984 Dec;7(6):725-7.PMID: 6543291 [PubMed - indexed for MEDLINE]Related articles

Evaluation of a sequential 5-FU and hydroxyurea combination in advanced bowel cancer.

Kao AK, Muggia FM, Dubin N, Lerner WA, Stark R, Wernz JC, Speyer JL, Blum RH.

Cancer Treat Rep. 1984 Nov;68(11):1383-5.PMID: 6498854 [PubMed - indexed for MEDLINE]Related articles

Phase II trial of 5-FU administered Ip to patients with refractory ovarian cancer.

Ozols RF, Speyer JL, Jenkins J, Myers CE.

Cancer Treat Rep. 1984 Oct;68(10):1229-32.PMID: 6525596 [PubMed - indexed for MEDLINE]Related articles